- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00003290
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomised Trial of High Dose Therapy in Localised Cancer of the Prostate Using Conformal Radiotherapy Techniques
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether standard radiation therapy is more effective than high-dose radiation therapy in treating patients with prostate cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of standard radiation therapy with that of high-dose radiation therapy in treating patients with stage II or stage III prostate cancer.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
OBJECTIVES:
- Compare local tumor control in patients with stage II or III prostate cancer treated with neoadjuvant androgen deprivation therapy with standard vs high-dose conformal radiotherapy.
- Compare the incidence of biochemical failure (prostate-specific antigen (PSA) greater than 2 ng/mL at 6 or more months after initiation of radiotherapy and PSA rising from nadir level by at least 50%), development of metastases, and survival in patients treated with these regimens.
- Compare the acute and late radiation-induced side effects of these regimens in this patient population.
- Compare aspects of quality of life, health economics, models of normal tissue, and tumor control in patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to prostate-specific antigen, T stage, and Gleason score. Patients are randomized to one of two treatment arms.
All patients receive neoadjuvant androgen deprivation with luteinizing hormone-releasing hormone agonists every 4 weeks beginning 3-6 months before initiation of radiotherapy and continuing until completion of radiotherapy.
- Arm I: Patients undergo standard conformal radiotherapy for 6.5 weeks.
- Arm II: Patients undergo high-dose conformal radiotherapy for 7.5 weeks. Quality of life is assessed at baseline, every 6 months for 2 years, and then annually thereafter.
Patients are followed every 6 months for 2 years and then annually thereafter.
PROJECTED ACCRUAL: A total of 800 patients will be accrued for this study.
Typ studie
Zápis (Očekávaný)
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
-
Cape Town, Jižní Afrika, 7925
- Groote Schuur Hospital, Cape Town
-
-
-
-
-
Preston, Spojené království, PR2 9HT
- Royal Preston Hospital
-
-
England
-
Birmingham, England, Spojené království, B15 2TT
- University of Birmingham
-
Bristol, England, Spojené království, BS2 8ED
- Bristol Haematology and Oncology Centre
-
Bristol, England, Spojené království, BS2 8BJ
- Bristol Royal Hospital for Children
-
Derby, England, Spojené království, DE1 2QY
- Derbyshire Royal Infirmary
-
Leeds, England, Spojené království, LS16 6QB
- Cookridge Hospital
-
Leicester, England, Spojené království, LE1 5WW
- University Hospitals of Leicester
-
London, England, Spojené království, WIT 3AA
- Middlesex Hospital- Meyerstein Institute
-
Manchester, England, Spojené království, M20 4BX
- Christie Hospital N.H.S. Trust
-
Merseyside, England, Spojené království, L63 4JY
- Clatterbridge Centre for Oncology NHS Trust
-
Newcastle Upon Tyne, England, Spojené království, NE4 6BE
- Newcastle General Hospital
-
Northwood, England, Spojené království, HA6 2RN
- Mount Vernon Hospital
-
Norwich, England, Spojené království, NR1 3SR
- Norfolk & Norwich Hospital
-
Oxford, England, Spojené království, 0X3 9DU
- Oxford Radcliffe Hospital
-
Sutton, England, Spojené království, SM2 5PT
- Royal Marsden Hospital
-
Westcliff-On-Sea, England, Spojené království
- Southend NHS Trust Hospital
-
-
Scotland
-
Edinburgh, Scotland, Spojené království
- Royal Hospital for Sick Children
-
Glasgow, Scotland, Spojené království, G11 6NT
- Beatson Oncology Centre
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dítě
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
DISEASE CHARACTERISTICS:
Histologically confirmed prostate cancer
- T1b-T3a, N0, M0 (stage II or III)
- Prostate-specific antigen at least 50 ng/mL
PATIENT CHARACTERISTICS:
Age:
- Not specified
Performance status:
- WHO 0-1
Life expectancy:
- Not specified
Hematopoietic:
- WBC greater than 4,000/mm^3
- Platelet count greater than 100,000/mm^3
- Hemoglobin greater than 11 g/dL
Hepatic:
- Not specified
Renal:
- Not specified
Other:
- No significant past medical history that would preclude radical radiotherapy
- No condition that would preclude standard radiotherapy
- No hip prosthesis
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- Not specified
Endocrine therapy:
- No prior androgen deprivation therapy
Radiotherapy:
- No prior pelvic radiotherapy
Surgery:
- No prior radical prostatectomy
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Studijní židle: David P. Dearnaley, MD, FRCP, FRCR, Royal Marsden NHS Foundation Trust
Publikace a užitečné odkazy
Obecné publikace
- Barnett GC, De Meerleer G, Gulliford SL, Sydes MR, Elliott RM, Dearnaley DP. The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clin Oncol (R Coll Radiol). 2011 Nov;23(9):613-24. doi: 10.1016/j.clon.2011.03.001. Epub 2011 Apr 5.
- South CP, Khoo VS, Naismith O, Norman A, Dearnaley DP. A comparison of treatment planning techniques used in two randomised UK external beam radiotherapy trials for localised prostate cancer. Clin Oncol (R Coll Radiol). 2008 Feb;20(1):15-21. doi: 10.1016/j.clon.2007.10.012. Epub 2007 Dec 3.
- van As N, South C, Naismith O, et al.: Radiotherapy planning in UK phase III trials of dose-escalated (MRC RT01) and high-dose hypofractionated radiotherapy (CHHIP) in prostate cancer. [Abstract] 2006 Prostate Cancer Symposium, February 24-26, 2006, San Francisco, CA. A-98, 2006.
- Mayles WP, Moore AR, Aird EG, Bidmead AM, Dearnaley DP, Griffiths SE, Warrington AP; RT01 collaborators. Questionnaire based quality assurance for the RT01 trial of dose escalation in conformal radiotherapy for prostate cancer (ISRCTN 47772397). Radiother Oncol. 2004 Nov;73(2):199-207. doi: 10.1016/j.radonc.2004.08.017.
- Sydes MR, Stephens RJ, Moore AR, Aird EG, Bidmead AM, Fallowfield LJ, Graham J, Griffiths S, Mayles WP, McGuire A, Stanley S, Warrington AP, Dearnaley DP; RT01 collaborators. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiother Oncol. 2004 Aug;72(2):199-211. doi: 10.1016/j.radonc.2004.04.007.
- Gulliford SL, Partridge M, Sydes MR, Webb S, Evans PM, Dearnaley DP. Parameters for the Lyman Kutcher Burman (LKB) model of Normal Tissue Complication Probability (NTCP) for specific rectal complications observed in clinical practise. Radiother Oncol. 2012 Mar;102(3):347-51. doi: 10.1016/j.radonc.2011.10.022. Epub 2011 Nov 25.
- Gulliford SL, Foo K, Morgan RC, Aird EG, Bidmead AM, Critchley H, Evans PM, Gianolini S, Mayles WP, Moore AR, Sanchez-Nieto B, Partridge M, Sydes MR, Webb S, Dearnaley DP. Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):747-54. doi: 10.1016/j.ijrobp.2009.02.025. Epub 2009 Jun 18.
- Syndikus I, Morgan RC, Sydes MR, Graham JD, Dearnaley DP; MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):773-83. doi: 10.1016/j.ijrobp.2009.05.052. Epub 2009 Oct 14.
- Stanley S, Griffiths S, Sydes MR, Moore AR, Syndikus I, Dearnaley DP; RT01 Radiographer Trial Implementation Group. Accuracy and reproducibility of conformal radiotherapy using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397). Clin Oncol (R Coll Radiol). 2008 Oct;20(8):582-90. doi: 10.1016/j.clon.2008.04.019. Epub 2008 Jun 18.
- Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J, Moore AR, Morgan RC, Russell JM, Scrase CD, Stephens RJ, Syndikus I, Parmar MK; RT01 collaborators. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007 Jun;8(6):475-87. doi: 10.1016/S1470-2045(07)70143-2.
- Dearnaley DP, Sydes MR, Langley RE, Graham JD, Huddart RA, Syndikus I, Matthews JH, Scrase CD, Jose CC, Logue J, Stephens RJ; RT01 Collaborators. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiother Oncol. 2007 Apr;83(1):31-41. doi: 10.1016/j.radonc.2007.02.014. Epub 2007 Mar 27.
- Mangar SA, Sydes MR, Tucker HL, Coffey J, Sohaib SA, Gianolini S, Webb S, Khoo VS; MRC RT01 Trial Management Group; Dearnaley DP. Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397). Radiother Oncol. 2006 Sep;80(3):355-62. doi: 10.1016/j.radonc.2006.07.037. Epub 2006 Sep 1.
- Dearnaley DP, Hall E, Lawrence D, Huddart RA, Eeles R, Nutting CM, Gadd J, Warrington A, Bidmead M, Horwich A. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer. 2005 Feb 14;92(3):488-98. doi: 10.1038/sj.bjc.6602301.
- Stephen M, Helen T, Matthew S, et al.: Evaluating the relationship between erectile dysfunction and dose received by the penile bulb in patients undergoing conformal radiotherapy for prostate cancer: analysis of data from the MRC RT01 dose escalation trial (ISRCTN47772397). [Abstract] Int J Radiat Oncol Biol Phys 63 (2 Suppl 1): A-209, S126, 2005.
- Stephens RJ, Cowan R, Dearnaley DP, et al.: The effect of hormone therapy on the quality of life of men with locally advanced prostate cancer (based on data from the MRC RT01 randomised trial (ISRCTN 47772397)). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1665, 414, 2003.
- Seddon B, Bidmead M, Wilson J, Khoo V, Dearnaley D. Target volume definition in conformal radiotherapy for prostate cancer: quality assurance in the MRC RT-01 trial. Radiother Oncol. 2000 Jul;56(1):73-83. doi: 10.1016/s0167-8140(00)00191-2.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- CDR0000066222
- MRC-RT01
- EU-98005
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na radiační terapie
-
Massachusetts General HospitalNational Cancer Institute (NCI); American Society of Clinical OncologyNáborFibróza myokardu | Rakovina prsu | Rakovina prsu II | Rakovina prsu žena | Rakovina prsu IIISpojené státy
-
University of Wisconsin, MadisonPozastavenoUrychlené částečné ozařování prsu v reálném čase MRI řízené 3 frakcemi u časné rakoviny prsu (MAPBI)Rakovina prsu | DCIS | LCISSpojené státy
-
Medical College of WisconsinAktivní, ne náborRakovina prostatySpojené státy
-
Case Comprehensive Cancer CenterDokončenoRakovina hlavy a krkuSpojené státy
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NáborRakovina hlavy a krku | Solidní nádoryČína
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)NáborPlaketa krční tepny | Stenóza karotid | Plak, aterosklerotickýSpojené státy
-
European Organisation for Research and Treatment...NáborOrofaryngeální rakovina | Hypofaryngeální spinocelulární karcinom | Supraglotický spinocelulární karcinomŠpanělsko, Belgie, Švýcarsko, Itálie, Spojené království, Německo, Francie, Polsko
-
University of California, IrvineNáborHPV pozitivní orofaryngeální spinocelulární karcinomSpojené státy
-
Imperial College LondonBiocompatibles UK Ltd, a BT International group companyNáborNeuroendokrinní nádory | Metastázy v játrechSpojené království
-
Johann Wolfgang Goethe University HospitalDokončenoChronická hepatitida CHolandsko, Německo, Francie